Abstract:BACKGROUND: Limited options exist for women with nausea and vomiting of pregnancy (NVP) who cannot tolerate oral intake. Transdermal delivery of granisetron, a 5-hydroxytryptamine-3 receptor antagonist, provides an effective alternative for such patients.OBJECTIVE: The objective of this study was to evaluate the pharmacodynamics of granisetron administered intravenously (IV) and as a sustained release transdermal patch in women with NVP.STUDY DESIGN: We recruited 16 women with singleton gestation between 12 0/7-18 6/7 weeks who were receiving treatment for NVP and had a Pregnancy Unique Quantification of Emesis and Nausea (PUQE) score of >= 6. All consenting subjects received 1 mg of granisetron as an IV infusion over 5 minutes and blood was obtained prior to the infusion and at 10, 20, 30, and 60 minutes and at 2, 4, 6, 8, 12, and 24 hours after the start of the infusion. After a minimum washout of 48 hours after initiation of IV granisetron, a 52-cm(2) granisetron patch (34.3 mg) was placed on the upper arm of all subjects for 7 days. Blood was drawn prior to patch placement and daily thereafter for 9 days. The subjects were evaluated daily. The PUQE score was obtained from these subjects prior to the IV infusion and daily for 2 days after and again prior to and daily for 9 days after patch placement.RESULTS: Complete data were available in 15 women after IV administration and 13 women after patch placement. One woman stopped participation during the IV infusion while data were not available in 2 additional women after patch placement due to noncompliance. Peak plasma granisetron concentrations after IV and transdermal administration were similar (w10 ng/mL). Prior to IV administration of granisetron, the PUQE score was 8.6 +/- 1.8 (mean +/- SD). The PUQE scores were significantly reduced for the ensuing 2 days (P < .01). The PUQE score prior to patch placement was 7.6 +/- 2.4. Scores were significantly (P < .001) reduced within 1 day of patch placement and stayed significantly reduced during the ensuing 6 days of patch placement. The patch was removed on the seventh day and PUQE scores increased significantly on the third day after patch removal. No serious side effects were reported either during IV administration or patch placement.CONCLUSION: Granisetron significantly improved symptoms of nausea and vomiting as gauged by the PUQE score. After IV infusion the reduction in PUQE score was observed within 1 day. When granisetron was administered as a patch, benefit likewise was seen within 1 day suggesting rapid absorption of the medication transdermally. The beneficial effect of transdermal granisetron on the PUQE score persisted for the entire 7 days during which the patch was in place. In this small cohort, the granisetron patch appeared to be efficacious in reducing the symptoms of nausea and vomiting. The patch provides another option for treating this disorder and may be particularly useful in women who cannot tolerate oral medications.

714: the Granisetron Patch is Effective in Reducing Nausea and Vomiting of Pregnancy (NVP)

Pharmacodynamics of Transdermal Granisetron in Women with Nausea and Vomiting of Pregnancy.

553: Pharmacokinetics of granisetron after IV and transdermal application in pregnancy

Clinical Study of Granisetron in the Prevention of Nausea and Vomiting Caused by Postoperative Epidural Analgesia

A Prospective, Randomized, Double-Blinded Study of the Effect of Intravenous Ondansetron on the Effective Dose in 50% of Subjects of Prophylactic Phenylephrine Infusions for Preventing Spinal Anesthesia–Induced Hypotension During Cesarean Delivery

Pharmacist-driven multidisciplinary initiative continuously improves postoperative nausea and vomiting in female patients undergoing abdominal surgery

The Effect of Palonosetron Hydrochloride in the Prevention of Chemotherapy-Induced Moderate and Severe Nausea and Vomiting

Transdermal Granisetron for the Prevention of Nausea and Vomiting Following Moderately or Highly Emetogenic Chemotherapy in Chinese Patients: a Randomized, Double-Blind, Phase III Study

Single-dose Tropisetron for prevention of Cisplatin-induced emesis

Transcutaneous Pericardium 6 Acupoint Electrical Stimulation Provides Comparable Antiemetic Effect to Granisetron When Combined With Dexamethasone in Patients Undergoing Breast Cancer Surgery

Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting

The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green‐top Guideline No. 69)

Polymorphisms Incyp1a1andcyp3a5genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting

To compare the effectiveness of granisetron versus ondansetron to control nausea and vomiting during lower segment cesarean section under subarachnoid block

Penehyclidine enhances the efficacy of tropisetron in prevention of PONV following gynecological laparoscopic surgery

Interventions for treating nausea and vomiting in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials

Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride

A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs

Efficacy of Low‐Dose Scopolamine and Palonosetron in Reducing Immediate Post‐Gastrointestinal Endoscopy Nausea and Vomiting: A Prospective, Randomized, Controlled Study

Acupuncture and Doxylamine–Pyridoxine for Nausea and Vomiting in Pregnancy

Effect of Palonosetron in Preventing Chemotherapy-Induced Vomiting